National HealthCare (NHC) stock has drawn fresh attention after recent trading, with the shares last closing at US$222.76. Investors are weighing this price against the company’s current fundamentals and recent return profile.
See our latest analysis for National HealthCare.
Although National HealthCare’s share price slipped around 1.5% over the last day and 3.6% over the past week, the stock still shows firm momentum, with a 31.5% 90 day share price return and a 134.9% 1 year total shareholder return.
If you are comparing National HealthCare with other growth stories in the market, this can be a useful moment to broaden your watchlist through the 41 healthcare AI stocks.
Bulls see National HealthCare’s recent 1 year and 3 year returns as a sign the market is catching up. Bears view the jump as froth. The valuation numbers help show which side the current evidence supports.
Preferred P/E of 28.1x: Is it justified?
On current numbers, National HealthCare trades on a P/E of 28.1x, which sits above the wider US Healthcare industry average but below its closer peer group.
The P/E multiple compares the share price with earnings per share. For a company like National HealthCare, which generates profits from established care facilities and services, this helps you see how much investors are paying for each dollar of earnings.
Management has delivered earnings growth of 14.6% over the past year and 1.4% per year over five years, and margins have edged higher to 8.1% from 7.9%. That mix suggests the market is paying up for a business with improving profitability, although the growth rate over a longer window looks more modest.
Compared with the US Healthcare industry average P/E of 25x, National HealthCare trades at a premium. Yet against its more direct peer set on 58.4x, the stock sits at a sizeable discount, which shows how divided valuations can be within the sector.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-earnings of 28.1x (ABOUT RIGHT)
However, National HealthCare still faces risks from changing reimbursement rules and any pressure on occupancy or care volumes that could challenge current earnings support for the P/E.
Find out about the key risks to this National HealthCare narrative.
Another view of National HealthCare’s value
The P/E points to a stock that is roughly in line with its earnings profile, yet the SWS DCF model paints a very different picture. With National HealthCare at $222.76 and an estimated future cash flow value of $636.06, this method suggests the shares trade at a steep discount. Which lens do you think provides the more useful perspective at this time?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out National HealthCare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals around National HealthCare’s valuation and outlook, this is a moment to look closely at the numbers and sentiment, then decide where you stand. To weigh up both sides of the story and judge the balance of concern and optimism for yourself, take a closer look at the 2 key rewards and 1 important warning sign
Looking for more National HealthCare sized investment ideas?
If you want to treat National HealthCare as just one piece of a broader plan, use the screeners below so you do not miss other potential opportunities.
- Target potential value opportunities across the market by scanning for companies on the 53 high quality undervalued stocks.
- Strengthen your income plan by reviewing stocks filtered through the 7 dividend fortresses.
- Prioritise resilience in your portfolio by checking companies highlighted in the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com